Disopyramide (Rythmodan) 100 mg: Supply issue

Supply issue Brand change Active

The current stock of Rythmodan available in New Zealand is short dated.

3 September 2026 | Alternative funded from 10 September

The supplier has found a new brand and it will be funded from 10 September 2026. The Neon Rythmodan will not be returning to New Zealand.

Details of the new brand

Affected product

It has been brought to our attention that the stock available of this product expires on 30 September 2026. 

Disopyramide phosphate

  • Presentation: Cap 100 mg
  • Brand: Rythmodan Neon (Section 29)
  • Pharmacode: 2713616
  • Subsidy: $55.90
  • Measure / Qty: per 84

Pharmac does not have a contract in place for the supply of this product.

Schedule listing for Rythmodan(external link)

New brand funded from 10 September

.
Japanese Rythmodan box and blister pack

The supplier has found another brand of Rythmodan. This will be funded from 10 September 2026. Like the current brand, it is not Medsafe approved. 

Packaging in English and Japanese

The box has one side in English and one side in Japanese. The capsule blister pack is mostly in Japanese. 

These capsules contain the same amount of active ingredient as the previous brands of Rythmodan.

The patient information leaflet that comes in the box is also in Japanese. 

Download an English translation of the patient information leaflet [PDF, 131 KB]

Listing information

Please note that the pack size has changed from 84 to 100.

  • Chemical: Disopyramide phosphate 
  • Brand: Rythmodan Cheplapharm
  • Presentation: Cap 100 mg
  • Subsidy: $66.56
  • Pharmacode: 2737221
  • Measure/Qty: per 100 

Section 29 and Wastage Rules apply.

Information for pharmacists

This listing will not appear in the Online Schedule until it is updated for 1 October 2026. It will appear automatically in RxOne, ScriptSense, and Toniq.

Pharmacists can claim as normal from 10 September 2026.

Flyer for patients

Neon brand not returning

The supplier advises that the Neon brand will not be returning to New Zealand. The Rythmodan Cheplapharm will be the funded brand for the foreseeable future.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

Sign up to our email list for regular emails about supply issues and more(external link)